A novel Omicron subvariant, BA.2, was found to be 1.5 times more transmissible than the original Omicron strain; analysis finds drugmakers increased list prices by 6.6% at the beginning of the year; alcohol consumption linked with the development of several cancer types.
As reported by CNBC, research on the Omicron subvariant, called BA.2, indicated that it is 1.5 times more transmissable than the original Omicron strain. As of this past Friday, the novel variant has been found in nearly half of US states and accounted for 127 cases nationwide, with other countries reporting growing circulation in proportion to Omicron. Although more infectious, early data has suggested that vaccines remain effective against the subvariant, with a booster dose shown to be 70% efficacious at preventing symptomatic illness.
According to findings of an analysis by Rx Savings Solutions, drugmakers increased list prices on cancer, diabetes, and other prescription drugs by 6.6% at the beginning of the year. Reported by The Wall Street Journal, 150 drugmakers raised prices on 866 products in the United States through January 20, in which price increases nearly matched the 7% overall consumer inflation rate—the highest rate in nearly 4 decades. Companies were found to keep most increases in the single digits as Congress continues to explore strategies to curb high drug costs.
Findings of a recent large-scale genetic study of Chinese adult populations linked the consumption of alcohol with the development of several types of cancer. As reported by Fox News, the main analysis focused primarily on men and investigated how the presence of specific alleles contributed to drinking habits. Data showed that the frequency of low-alcohol tolerability alleles was 21% for aldehyde dehydrogenase 2 and 69% for alcohol dehydrogenase 1B, with the low-tolerability alleles strongly linked to reduced alcohol consumption and lower cancer incidence in men. Overall, 7.4% of male participants developed cancer during the follow-up period.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Study Highlights Disparities in Access to In-Network Mental Health Care vs Medical Care
April 17th 2024While health plans often employ reimbursement rates as a tool to incentivize provider participation within their networks, study results showed reimbursement rates for office visits with medical/surgical clinicians were on average 22% higher than behavioral health clinicians.
Read More